PhagoMed Biopharma GmbH CEO Alexander Belcredi spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The Austria-based biotech's pipeline is focused on treating biofilm-forming bacterial infections, which are all in preclinical development. The company specializes in fighting multi-resistant bacteria, where multiple antibiotics have become ineffective.
PhagoMed looks to raise around $18M to scale up its bacterial infections treatment
